CARRA, ERNEST,GERBER, MICHAEL,SHI, BING,SUJINO, KEIKO,TRAN, DUONG,WANG, FANG,EVARTS, JERRY B.
申请号：
PE0013102014
公开号：
PE17922014A1
申请日:
2013.03.05
申请国别(地区):
PE
年份:
2014
代理人:
摘要：
Refers to polymorphs of (S) - 2 - (1 - (9H purin - 6 - ilamino) propyl) - 5 - fluoro - 3 - fenilquinazolin - 4 (3H) - One such as I) the way I which has a pattern of x-ray Powder diffraction Peaks which includes characteristic 14.3 20.9, 17.2, and 23.9 degrees 2? Form II and (ii) that has a pattern of x-ray Powder diffraction Peaks which includes characteristic 14.0, 18.6 and 24.3 degrees 2? .Also refers to Preparation procedures and to a Pharmaceutical composition comprising a mixture of polymorphic Form I and II. These polymorphs are PI 3-kinase inhibitors being useful in the treatment of cancerSE REFIERE A POLIMORFOS DE (S)-2-(1-(9H-PURIN-6-ILAMINO)PROPIL)-5-FLUOR-3-FENILQUINAZOLIN-4(3H)-ONA TALES COMO i) LA FORMA I QUE TIENE UN PATRON DE DIFRACCION DE POLVO DE RAYOS X QUE COMPRENDE PICOS CARACTERISTICOS A 14.3, 17.2, 20.9 Y 23.9 GRADOS 2? Y ii) LA FORMA II QUE TIENE UN PATRON DE DIFRACCION DE POLVO DE RAYOS X QUE COMPRENDE PICOS CARACTERISTICOS A 14.0, 18.6 Y 24.3 GRADOS 2?. TAMBIEN SE REFIERE A PROCEDIMIENTOS DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA MEZCLA DE LA FORMA POLIMORFICA I Y II. DICHOS POLIMORFOS SON INHIBIDORES DE PI 3-QUINASA SIENDO UTILES EN EL TRATAMIENTO DEL CANCER
